Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ac-201 + febuxostat
- Development stage
- Unknown
- Lead developer
- Accro Bioscience
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**ac-201 + febuxostat** is an investigational combination therapy consisting of AC-201, a selective oral inhibitor of TYK2 and JAK1, and febuxostat, a xanthine oxidase inhibitor. AC-201 targets cytokine signaling (notably TYK2/JAK1-dependent inflammatory pathways) and has demonstrated urate-lowering and anti-inflammatory effects, including inhibition of caspase-1 and interleukin-1β production and activity[1][2][4][6][7]. Febuxostat is primarily used as urate-lowering therapy by inhibiting xanthine oxidase, thereby reducing serum uric acid levels. The combination is being studied for synergistic urate-lowering effects and for prophylaxis against gout flares during urate-lowering therapy initiation[1][5]. AC-201 is being developed by Accropeutics (Accro Bioscience (Suzhou)), with febuxostat already widely approved.
- Other names
- ac-201 + febuxostat
02
Targets
Beyond the preview
Go deeper on ac-201 + febuxostat.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ac-201 + febuxostat.